A 24-week, prospective, pilot, randomized, open, parallel-group, active-comparator controlled trial to study dapagliflozin may attenuate adipose tissue inflammation and arterial stiffness in type 2 diabetes.
Phase of Trial: Phase II
Latest Information Update: 28 Jul 2015
At a glance
- Drugs Dapagliflozin (Primary) ; Saxagliptin
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- 28 Jul 2015 New trial record
- 09 Jun 2015 Results presented at the 75th Annual Scientific Sessions of the American Diabetes Association.